In a large randomized trial with COVID-19 patients, treatment with dapagliflozin, a SGLT2 inhibitors, did not result in a statistically significant risk reduction in organ dysfunction and death, or speedier recovery [65]. Here, SLC5A2 is linked to COVID-19.